CLAIMS OF THE APPLICATION:

- 1. (Original) A tablet comprising a drug substance that is susceptible to polymorphic conversion, the tablet having been formed by compression with forces sufficiently low to maintain the drug in its original polymorphic form.
- 2. (Original) The tablet according to claim 1, wherein the drug substance is amorphous.
- 3. (Original) The tablet according to claim 2, wherein no greater than about 10 weight percent of the amorphous drug substance is crystalline.
- 4. (Original) The tablet according to claim 1, wherein compression is conducted between about 0.2 and about 5 tons.
- 5. (Original) The tablet according to claim 1, wherein compression is conducted between about 0.2 and about 3 tons.
- 6. (Original) The tablet according to claim 1, wherein a maximum tablet dimension is about 3 mm.
- 7. (Original) The tablet according to claim 1, wherein a maximum tablet dimension is about 1 mm to about 3 mm.
- 8. (Original) A pharmaceutical dosage form comprising a plurality of tablets prepared according to claim 1, contained within a capsule.
- 9. (Original) A pharmaceutical dosage form, comprising a plurality of particles formed by:
- (a) mixing a drug substance that is susceptible to polymorphic conversion, with one or more pharmaceutically acceptable excipients;

- (b) compressing the mixture at about 0.2 tons to about 5 tons, to form particles; and
 - (c) filling a plurality of the particles into a capsule.
- 10. (Original) The pharmaceutical dosage form according to claim 9, wherein the drug substance is amorphous.
- 11. (Original) The pharmaceutical dosage form according to claim 9, wherein no greater than about 10 weight percent of the drug substance is crystalline.
- 12. (Original) The pharmaceutical dosage form according to claim 9, wherein compressing is conducted at about 0.2 tons to about 3 tons.
- 13. (Original) The pharmaceutical dosage form according to claim 9, wherein a maximum particle dimension is about 3 mm.
- 14. (Original) A method of preparing a pharmaceutical dosage form, comprising:
- (a) forming a mixture comprising a drug substance that is susceptible to polymorphic conversion, with one or more pharmaceutically acceptable excipients; and
- (b) compressing the mixture at about 0.2 tons to about 5 tons, to form particles.
- 15. (Original) The method according to claim 14, wherein particles have a maximum dimension no greater than about 3 mm.
- 16. (Original) The method according to claim 14, wherein the drug is amorphous.
- 17. (Original) The method according to claim 14, further comprising applying a coating to the particles.

- 18. (Original) The method according to claim 14, wherein compression is conducted at about 0.2 tons to about 3 tons.
- 19. (Original) The method according to claim 14, wherein a maximum dimension is about 1 mm to about 3 mm.
- 20. (Original) The method according to claim 14, further comprising placing a plurality of particles into a capsule.
- 21. (New) The tablet according to claim 1, wherein a drug substance comprises esomeprazole magnesium.
- 22. (New) The pharmaceutical dosage form according to claim 9, wherein a drug substance comprises esomeprazole magnesium.
- 23. (New) The method according to claim 14, wherein a drug substance comprises esomeprazole magnesium.